"NEW YORK (Reuters Health) - The combination of conjugated estrogens with bazedoxifene (CE/BZA) significantly improves bone mineral density (BMD) and bone turnover, according to pooled results from the SMART-1 and SMART-5 trials.
Overdosage of estrogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of OGEN therapy with institutions of appropriate symptomatic care.
OGEN therapy should not be used in women with any of the following conditions:
- Undiagnosed abnormal genital bleeding.
- Known, suspected, or history of breast cancer.
- Known or suspected estrogen-dependent neoplasia.
- Active DVT, PE or a history of these conditions.
- Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions.
- Known anaphylactic reaction or angioedema to OGEN tablets.
- Known liver dysfunction or disease.
- Known protein C, protein S, or anthithrombin deficiency or other known thrombophilic disorders.
- Known or suspected pregnancy.
Last reviewed on RxList: 1/9/2017
Additional Ogen Information
Ogen - User Reviews
Ogen User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.